Literature DB >> 11741629

Prescription-event monitoring and reporting of adverse drug reactions.

E Heeley1, J Riley, D Layton, L V Wilton, S A Shakir.   

Abstract

Newly marketed drugs in the UK are marked with a black triangle, indicating that doctors should report all adverse drug reactions associated with them to the Committee on Safety of Medicines (CSM). However, under-reporting of adverse reactions is frequent. Our aim was to establish what types of adverse reactions are under-reported to the CSM by family doctors who work in England. We used prescription-event monitoring data obtained for 15 newly marketed drugs. Only 9% (376) of 4211 events found on prescription-event monitoring were reported to the CSM. However, 53% (27) of 51 events classified as serious adverse drug reactions were reported. Overall, serious events were five times more likely to be reported to the CSM than non-serious events. Our results should not be extrapolated to calculate incidence rates of adverse drug reactions in the community from spontaneous reports.

Mesh:

Year:  2001        PMID: 11741629     DOI: 10.1016/S0140-6736(01)06898-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  40 in total

1.  Examining the utilization and tolerability of the non-sedating antihistamine levocetirizine in England using prescription-event monitoring data.

Authors:  Deborah Layton; Vicki Osborne; Anna Gilchrist; Saad A W Shakir
Journal:  Drug Saf       Date:  2011-12-01       Impact factor: 5.606

Review 2.  Advances in targeted therapy: safety of biological agents.

Authors:  E C Keystone
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

3.  Comparison of the risk of drowsiness and sedation between levocetirizine and desloratadine: a prescription-event monitoring study in England.

Authors:  Deborah Layton; Lynda Wilton; Andrew Boshier; Victoria Cornelius; Scott Harris; Saad A W Shakir
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

4.  Comparison of hospital episodes with 'drug-induced' disorders and spontaneously reported adverse drug reactions.

Authors:  Paul Barrow; Patrick Waller; Lesley Wise
Journal:  Br J Clin Pharmacol       Date:  2006-02       Impact factor: 4.335

5.  An assessment of the publicly disseminated evidence of safety used in decisions to withdraw medicinal products from the UK and US markets.

Authors:  Andrea Clarke; Jonathan J Deeks; Saad A W Shakir
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

6.  The influence of primary care prescribing rates for new drugs on spontaneous reporting of adverse drug reactions.

Authors:  Richard C Clark; Simon R J Maxwell; Sheena Kerr; Melinda Cuthbert; Duncan Buchanan; Doug Steinke; David J Webb; Nicholas D Bateman
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 7.  Acute dystonic reaction caused by metoclopramide, versus tetanus.

Authors:  Kyra Dingli; Rhoda Morgan; Clifford Leen
Journal:  BMJ       Date:  2007-04-28

8.  Examining the tolerability of the non-sedating antihistamine desloratadine: a prescription-event monitoring study in England.

Authors:  Deborah Layton; Lynda Wilton; Saad A W Shakir
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

9.  The pharmacovigilance of pantoprazole: the results of postmarketing surveillance on 11 541 patients in England.

Authors:  Lynda V Wilton; Cheryl Key; Saad A W Shakir
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

10.  Adverse drug reaction reporting among health care workers at Mulago National Referral and Teaching hospital in Uganda.

Authors:  Barbra Katusiime; Daniel Semakula; Solomon J Lubinga
Journal:  Afr Health Sci       Date:  2015-12       Impact factor: 0.927

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.